On February 23, a report on NewScientist suggested the UK and California variants of coronavirus appear to have combined into a heavily mutated hybrid, sparking concern that we may be entering a new phase of the COVID-19 pandemic. The new mutants of COVID-19 comes in two forms labeled B.1.1.7 (the number of spike mutations: 9; mutation site: N501Y) and B.1.429 (the number of spike mutations: 3; mutation site: L452R). Mutations of SARS-CoV-2 at the spike proteins, especially at the receptor binding domain (RBD), is significantly increasing its ability to infect. Scientists still have more questions than answers about the new mutant strains. At present, so many of the world’s researchers focused so urgently on certain mutations including D614G and E484K.
CUSABIO, has been continuously developing the best products and related custom service to enable researchers to better conduct research. Here we collect a panel of recombinant RBD/Spike and nucleocapsid protein variants to support our researchers, which might accelerate the antibody design and vaccine implementation for our scientists.
SARS-CoV-2 Spike S1 Mutant
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind Biotinylated Anti-SARS-CoV-2-S Antibody (CSB-RA33245D1GMY), the EC50 is 106.2-131.2 ng/ml.
As the COVID-19 pandemic evolves, we are with you during these turbulent times. CUSABIO appreciates the critical role that you and our products play in research efforts to further scientific innovation and discovery. We know that many scientists are diligently pursuing their research throughout the pandemic. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.